This article appears in the the BreastCancerUpdate Journal Vol 5. The article is edited by Mark D Pegram MD
Associate Professor of Medicine David Geffen School of Medicine at UCLA Director Women’s Cancer Program UCLA/Jonsson Comprehensive Cancer Center. Dr. Pegram covers many topics relevant to HER-2 positive breast cancer treatment including: Early Phase I experience with trastuzumab/cisplatin in metastatic disease Phase III randomized trial of trastuzumab/paclitaxel with or without carboplatin Trastuzumab/platinum/taxane regimens First-line therapy for patients with HER2-positive metastatic disease BCIRG-006 adjuvant trastuzumab trial Adjuvant trastuzumab in the nonprotocol setting Influence of trastuzumab therapy on tumor HER2 status Trials combining trastuzumab with hormonal therapy Fulvestrant in clinical practice Potential synergy between fulvestrant and trastuzumab Trials combining trastuzumab with biologic agents (i.e. Erlotinib and Bevacizumab) Treatment options for patients with ER-negative HER2- negative metastatic disease Transition from hormonal therapy to chemotherapy Phase III trial comparing capecitabine with or without bevacizumab ECOG-E-2100: Phase III trial comparing paclitaxel with or without bevacizumab Use of adjuvant dose-dense chemotherapy schedules As you know Dr. Dennis Slamon (father of Herceptin/trastuzumab) is based at UCLA. I find the articles written or edited by the doctors at UCLA insightful. Of course all treatment options should be discussed fully with your doctor. |
All times are GMT -7. The time now is 05:34 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021